Mereo BioPharma Group PLC ADR 0A9G
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 0A9G is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $3.99
- Day Range
- $4.08–4.36
- 52-Week Range
- $1.10–4.36
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $600.37 Mil
- Volume/Avg
- 13,438 / 3,609
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 58.08
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 33
- Website
- https://www.mereobiopharma.com
Valuation
|
Metric
|
0A9G
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 14.01 |
Price/Sales | 58.08 |
Price/Cash Flow | — |
Price/Earnings
0A9G
Financial Strength
|
Metric
|
0A9G
|
|---|---|
Quick Ratio | 4.62 |
Current Ratio | 4.86 |
Interest Coverage | −11.26 |
Quick Ratio
0A9G
Profitability
|
Metric
|
0A9G
|
|---|---|
Return on Assets (Normalized) | −25.60% |
Return on Equity (Normalized) | −34.53% |
Return on Invested Capital (Normalized) | −30.30% |
Return on Assets
0A9G
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Vrdwvnw | Rftrpr | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hzkxhxvg | Qklfww | $114.2 Bil | |||
| Moderna Inc
MRNA
| Bhjrgwgcx | Nkz | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Lsmvppf | Cxj | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Qzxhrfxgy | Dhpw | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Rzpwdmfz | Rgmmjd | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Rnvqvzp | Wygrgmm | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Cdqfkxx | Smq | $12.8 Bil | |||
| Incyte Corp
INCY
| Srnyybpd | Tnkmkbz | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Vjyzvmgd | Sbqrdm | $12.2 Bil |